Log in

Nevro Stock Forecast, Price & News

-2.70 (-1.70 %)
(As of 12/3/2020 12:00 AM ET)
Today's Range
Now: $156.59
50-Day Range
MA: $161.19
52-Week Range
Now: $156.59
Volume289,351 shs
Average Volume397,296 shs
Market Capitalization$5.39 billion
P/E RatioN/A
Dividend YieldN/A
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. It also offers Senza II system and Senza Omnia system products for chronic pain. The company's solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. Nevro Corp. sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was founded in 2006 and is headquartered in Redwood City, California.
Nevro logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.20 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments



Sales & Book Value

Annual Sales$390.26 million
Book Value$6.98 per share


Net Income$-103,690,000.00


Market Cap$5.39 billion
Next Earnings Date2/23/2021 (Estimated)
-2.70 (-1.70 %)
(As of 12/3/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Nevro (NYSE:NVRO) Frequently Asked Questions

How has Nevro's stock price been impacted by COVID-19 (Coronavirus)?

Nevro's stock was trading at $109.82 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVRO shares have increased by 42.6% and is now trading at $156.59.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Nevro?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Nevro
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Nevro?

Wall Street analysts have given Nevro a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nevro wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Nevro's next earnings date?

Nevro is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Nevro

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) released its quarterly earnings data on Thursday, November, 5th. The medical equipment provider reported ($0.29) EPS for the quarter, beating the Zacks' consensus estimate of ($0.59) by $0.30. The medical equipment provider had revenue of $108.46 million for the quarter, compared to analyst estimates of $104 million. Nevro had a negative net margin of 27.22% and a negative return on equity of 38.86%. The firm's revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.58) earnings per share.
View Nevro's earnings history

What price target have analysts set for NVRO?

13 Wall Street analysts have issued 12 month price targets for Nevro's stock. Their forecasts range from $100.00 to $190.00. On average, they expect Nevro's stock price to reach $155.36 in the next twelve months. This suggests that the stock has a possible downside of 0.8%.
View analysts' price targets for Nevro

Who are some of Nevro's key competitors?

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), The Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

Who are Nevro's key executives?

Nevro's management team includes the following people:
  • Mr. D. Keith Grossman, Chairman, CEO & Pres (Age 60, Pay $1.6M)
  • Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 46, Pay $705.96k)
  • Mr. Michael Collier Carter, VP of Global Sales (Age 48, Pay $841.82k)
  • Mr. Andrew H. Galligan, Exec. Officer (Age 64, Pay $812.72k)
  • Ms. Niamh Louise Pellegrini, Chief Commercial Officer (Age 53, Pay $853.27k)
  • Mr. Roderick H. MacLeod, Chief Financial Officer
  • Mr. Patrick Schmitz, VP of Operations (Age 60)
  • Ms. Juliet Cunningham, VP of Investor Relations
  • Mr. Neeraj Teotia, VP of Marketing (Age 45)
  • Ms. Lori M. Ciano, Chief HR Officer (Age 57)

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Who are Nevro's major shareholders?

Nevro's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (10.15%), Jackson Square Partners LLC (2.99%), Lord Abbett & CO. LLC (2.16%), State Street Corp (2.09%), Victory Capital Management Inc. (1.27%) and Jennison Associates LLC (1.08%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends for Nevro

Which institutional investors are selling Nevro stock?

NVRO stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Tiger Eye Capital LLC, Jackson Square Partners LLC, State Street Corp, Sei Investments Co., Robeco Institutional Asset Management B.V., First Trust Advisors LP, and Thrivent Financial for Lutherans. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Michael F Demane, Niamh Louise Pellegrini, and Shawn Mccormick.
View insider buying and selling activity for Nevro

Which institutional investors are buying Nevro stock?

NVRO stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Point72 Asset Management L.P., Lord Abbett & CO. LLC, Summit Partners Public Asset Management LLC, Granite Investment Partners LLC, Victory Capital Management Inc., Squarepoint Ops LLC, and BlackRock Inc.. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman, and Kevin C Oboyle.
View insider buying and selling activity for Nevro

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $156.59.

How big of a company is Nevro?

Nevro has a market capitalization of $5.39 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Nevro employs 853 workers across the globe.

What is Nevro's official website?

The official website for Nevro is www.nevro.com.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.